ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
48 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
48
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Phaedrus
|
168 |
112K |
38 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
168
|
112K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Proposed issue of securities - MSB
|
|
Phaedrus
|
18 |
6.3K |
3 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
18
|
6.3K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
15 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
Phaedrus
|
154 |
52K |
13 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
52K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
Phaedrus
|
154 |
52K |
5 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
52K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
Phaedrus
|
154 |
52K |
1 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
52K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
Phaedrus
|
154 |
52K |
21 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
52K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
Phaedrus
|
154 |
52K |
6 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
52K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
6 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
51 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
1 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
12 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
6 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
9 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
9 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
549
|
190K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
7 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
190K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
1 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
11 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
190K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
6.0K |
3.0M |
9 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
6.0K
|
3.0M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
42 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
549
|
190K
|
42
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
41 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
190K
|
41
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
15 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
190K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
16 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
943
|
417K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
29 Feb HY Conference Call Transcript
|
|
Phaedrus
|
23 |
8.3K |
5 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
23
|
8.3K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
29 Feb HY Conference Call Transcript
|
|
Phaedrus
|
23 |
8.3K |
6 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
23
|
8.3K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
29 Feb HY Conference Call Transcript
|
|
Phaedrus
|
23 |
8.3K |
13 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
23
|
8.3K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Phaedrus
|
168 |
112K |
1 |
03/03/24 |
03/03/24 |
ASX - By Stock
|
168
|
112K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Phaedrus
|
168 |
112K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
168
|
112K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Phaedrus
|
168 |
112K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
168
|
112K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Phaedrus
|
78 |
27K |
8 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
27K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Report and Accounts (including Appendix 4D)
|
|
Phaedrus
|
31 |
10K |
6 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
31
|
10K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Report and Accounts (including Appendix 4D)
|
|
Phaedrus
|
31 |
10K |
26 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
31
|
10K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
Phaedrus
|
62 |
24K |
5 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
62
|
24K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Phaedrus
|
362 |
127K |
13 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
362
|
127K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2024 Half Year Financial Results Webcast
|
|
Phaedrus
|
62 |
24K |
18 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
62
|
24K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Phaedrus
|
362 |
127K |
94 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
362
|
127K
|
94
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
13 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
18K
|
7.1M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
36 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
18K
|
7.1M
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
6 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
18K
|
7.1M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Colitis Indication
|
|
Phaedrus
|
19 |
7.3K |
3 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
19
|
7.3K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Colitis Indication
|
|
Phaedrus
|
19 |
7.3K |
40 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
19
|
7.3K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
12K |
3.9M |
22 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
12K
|
3.9M
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil - potency assay data
|
|
Phaedrus
|
15 |
5.5K |
28 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
15
|
5.5K
|
28
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Phaedrus
|
362 |
127K |
1 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
362
|
127K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
|
|
Phaedrus
|
362 |
127K |
2 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
362
|
127K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor
|
|
Phaedrus
|
380 |
135K |
3 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
380
|
135K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor
|
|
Phaedrus
|
380 |
135K |
8 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
380
|
135K
|
8
|
|